北京
分享至
FDA批准阿斯利康与第一三共的fam-trastuzumab deruxtecan联合帕妥珠单抗用于一线治疗，因DESTINY-Breast09试验显示其中位无进展生存期达40.7个月，优于标准THP方案的26.9个月；帕妥珠单抗由罗氏销售。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
